Citation Impact
Citing Papers
HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer
2009
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
2009 StandoutNobel
Complex organochlorine pesticide mixtures as determinant factor for breast cancer risk: a population-based case–control study in the Canary Islands (Spain)
2012
Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met
1999
Impact of endocrine disruptor chemicals in gynaecology
2007
Mammographic Density and the Risk and Detection of Breast Cancer
2007 Standout
A novel DNA vaccine encoding PDGFRβ suppresses growth and dissemination of murine colon, lung and breast carcinoma
2006
PDGF-C Induces Maturation of Blood Vessels in a Model of Glioblastoma and Attenuates the Response to Anti-VEGF Treatment
2009
CD44: From adhesion molecules to signalling regulators
2003 Standout
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation
1995
Molecular imaging in living subjects: seeing fundamental biological processes in a new light
2003 Standout
Endogenous Hormone Levels, Mammographic Density, and Subsequent Risk of Breast Cancer in Postmenopausal Women
2007
Hepatocyte growth factor/scatter factor—Met signaling in tumorigenicity and invasion/metastasis
1996
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
2004
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Obesity, adipocytokines, and insulin resistance in breast cancer
2004
The MET axis as a therapeutic target
2009
The biology and function of fibroblasts in cancer
2016 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Combined Screening With Ultrasound and Mammography vs Mammography Alone in Women at Elevated Risk of Breast Cancer
2008 Standout
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
2002
Increased emotional distress in daughters of breast cancer patients is associated with decreased natural cytotoxic activity, elevated levels of stress hormones and decreased secretion of Th1 cytokines
2002
The molecular biology of head and neck cancer
2010 Standout
Functions of natural killer cells
2008 Standout
Antibody therapy of cancer
2012 Standout
Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function
2004 StandoutNobel
Biology of Natural Killer Cells
1989 Standout
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Drug development of MET inhibitors: targeting oncogene addiction and expedience
2008
Electropotential measurements as a new diagnostic modality for breast cancer
1998
DDT/DDE and breast cancer: A meta-analysis
2013
Angiogenesis in life, disease and medicine
2005 StandoutNature
Cancer as an overhealing wound: an old hypothesis revisited
2008 Standout
C-MET as a new therapeutic target for the development of novel anticancer drugs
2010
Organochlorines and Risk of Prostate Cancer
2003
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
2004
Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in primary culture of human mammary fibroblasts
2004
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting
2008
Co-operative Effect of c-Src Tyrosine Kinase and Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary Carcinoma Cells
2001
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
2008 Standout
Met, metastasis, motility and more
2003 Standout
Paradoxical roles of the immune system during cancer development
2006 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
The STATs of cancer — new molecular targets come of age
2004 Standout
Wild-Type But Not Mutant p53 Activates the Hepatocyte Growth Factor/Scatter Factor Promoter
1997
Controlling Cell Behavior Electrically: Current Views and Future Potential
2005 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Plasma organochlorine levels and prostate cancer risk
2009
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans.
2007 Standout
Modes of resistance to anti-angiogenic therapy
2008 Standout
Quantitative Assessment of Mammographic Breast Density: Relationship with Breast Cancer Risk
2004
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Platelet-derived growth factor plays a critical role to convert bone marrow cells into glomerular mesangial-like cells
2003 StandoutNobel
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
2006 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
The hallmarks of CAFs in cancer invasion
2016
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
2006 Standout
VEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
2004
Tumorigenesis and the angiogenic switch
2003 Standout
Racial differences in mammographic breast density
2003
Increased levels of dioxin-like substances in adipose tissue in patients with deep infiltrating endometriosis
2015
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity
1999 StandoutNobel
Breast Cancer Risk and the Combined Effect of Environmental Estrogens
2004
Association of serum adiponectin levels with breast cancer risk.
2003
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
2009 Standout
Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor
1997
Diabetes and Cancer
2010 Standout
In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors.
2001
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Degradation of the Met Tyrosine Kinase Receptor by the Ubiquitin-Proteasome Pathway
1997 StandoutNobel
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.
1993 Standout
Transcriptional control of human p53-regulated genes
2008 Standout
Modulatory effects of neonatal exposure to TCDD, or a mixture of PCBs, p,p'-DDT, and p-p'-DDE, on methylnitrosourea-induced mammary tumor development in the rat.
2001
The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells
1999 StandoutNobel
Inhibition of Platelet-Derived Growth Factor Receptor Signaling Restricts the Growth of Human Breast Cancer in the Bone of Nude Mice
2005
The mutationally activated Met receptor mediates motility and metastasis
1998
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
2000
Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2008
NATURAL KILLER CELLS IN ANTIVIRAL DEFENSE: Function and Regulation by Innate Cytokines
1999 Standout
Regulation of Wound Healing by Growth Factors and Cytokines
2003 Standout
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
2004 Standout
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
1999 Standout
Microvessel Density as a Prognostic Factor in Women with Breast Cancer
2004
Works of Ernest E. Sterns being referenced
Macromolecular interstitial clearance, tumour vascularity, other prognostic factors and breast cancer survival
1997
Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable?
2000
Mammographic density in women on postmenopausal hormone replacement therapy
1997
Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma.
1996
Age-related breast diagnosis.
1992
Natural killer cell activity in women at “high risk” for breast cancer, with and without benign breast syndrome
1984
Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma.
1996
Breast adipose tissue concentrations of polychlorinated biphenyls and other organochlorines and breast cancer risk.
2000
Plasma Concentrations of C-19 Steroids, Estrogens, FSH, LH and Prolactin in Post-Menopausal Women with and without Breast Cancer
1981